Outlook Therapeutics, Inc. (NASDAQ:OTLK) shares saw unusually-strong trading volume on Monday . Approximately 6,324,501 shares were traded during mid-day trading, an increase of 2,013% from the previous session’s volume of 299,311 shares.The stock last traded at $1.04 and had previously closed at $0.92.
Separately, ValuEngine lowered Outlook Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, January 29th.
Outlook Therapeutics Company Profile (NASDAQ:OTLK)
Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases.
See Also: Understanding Analyst Ratings
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.